Security record · archived quarter
TLRY
Tilray Brands, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
3Tracked holders
—Δ holders
3.47MShares held
$6.55MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 68 | +10 | 11.57M | $51.96M | +11 | −1 |
| Q1 2026 | 61 | 0 | 8.60M | $55.69M | +8 | −8 |
| Q4 2025 | 62 | -1 | 8.71M | $78.67M | — | −1 |
| Q3 2025 | 13 | +1 | 26.08M | $45.11M | +1 | — |
| Q2 2025 | 9 | -1 | 20.61M | $8.54M | — | −1 |
| Q1 2025 | 7 | +2 | 4.27M | $2.81M | +2 | — |
| Q4 2024 | 5 | -2 | 7.93M | $11.46M | +1 | −3 |
| Q3 2024 | 6 | +3 | 5.26M | $10.08M | +4 | −1 |
| Q2 2024 | 3 | — | 3.47M | $6.55M | — | — |
Who holds it · Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 2.09M | — | $4.26M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | D. E. Shaw & Co. ✦ | 1.25M | — | $2.07M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Millennium Management ✦ | 126.50K | — | $209,988 | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Millennium Management ✦ | 126.50K | — | $209,988 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 24.30K shares, $157 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2024 ·
Methodology ·
Get this via the API